Some studies showed that AMPK activation enhances the cytotoxicity of anti-EGFR antibodies to CRC cells with KRAS mutation, such as DLD-1 and SW480 [38], supporting the potential use of adenine as an adjuvant in the treatment of CRC. Here, PRKAA1 is linked to colorectal carcinoma.